SOP for Remote/eConsent (Part 11/GDPR-Compliant)

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-remote-econsent-part-11-gdpr-compliant”
},
“headline”: “SOP for Remote/eConsent (Part 11/GDPR-Compliant)”,
“description”: “This SOP outlines procedures for implementing remote electronic informed consent (eConsent) in clinical trials, ensuring compliance with FDA 21 CFR Part 11, GDPR, HIPAA, and ICH GCP. It covers subject identity verification, data privacy, IRB/EC approvals, audit trails, and inspection readiness.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Published on 27/12/2025

Standard Operating Procedure for Remote/eConsent (Part 11/GDPR-Compliant)

SOP No.	CR/OPS/121/2025
Supersedes	NA
Page No.	1 of 67
Issue Date	26/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Table of Contents

Purpose

The purpose of this SOP is to define standardized procedures for implementing remote and electronic informed consent (eConsent) in clinical trials. It ensures compliance with FDA

21 CFR Part 11, EMA eConsent guidelines, GDPR, HIPAA, and ICH GCP, while safeguarding subject autonomy, comprehension, and data privacy.

Scope

This SOP applies to sponsors, investigators, CROs, regulatory affairs teams, and site staff involved in trials that use remote/eConsent solutions. It covers system validation, subject identity verification, data protection, IRB/EC approval, audit trails, and inspection readiness.

Responsibilities

Sponsor: Ensures validated eConsent platforms, oversees vendor compliance, and provides training.
Investigator: Explains consent process, ensures subject comprehension, and verifies eConsent completion.
Site Staff: Support subjects during eConsent and maintain documentation.
CRO: Monitors eConsent implementation and reports deviations.
IRB/EC: Reviews and approves eConsent forms, language, and technology use.
QA: Audits eConsent systems and ensures regulatory compliance.

Accountability

The Sponsor’s Regulatory Compliance Officer is accountable for eConsent system validation and data privacy compliance. Principal Investigators are accountable for obtaining subject consent in line with this SOP.

Procedure

1. System Validation
1.1 Use platforms compliant with FDA 21 CFR Part 11, GDPR, and HIPAA.
1.2 Validate software before deployment.
1.3 Record in eConsent System Validation Log (Annexure-1).

2. IRB/EC Approval
2.1 Submit eConsent forms and digital tools for review.
2.2 Maintain approval records in EC/IRB Approval Log (Annexure-2).

3. Subject Identity Verification
3.1 Verify subject identity via secure authentication methods (e.g., OTP, ID upload).
3.2 Document verification in Identity Verification Log (Annexure-3).

4. Consent Process
4.1 Provide multimedia consent materials (text, video, audio).
4.2 Ensure comprehension through quizzes or acknowledgment checks.
4.3 Record in eConsent Completion Log (Annexure-4).

5. Documentation
5.1 Maintain complete audit trails including timestamps and digital signatures.
5.2 Store records in validated electronic systems.
5.3 Archive in TMF and ISF.

6. Data Privacy
6.1 Ensure GDPR-compliant data handling.
6.2 Protect subject identifiers through encryption and access controls.
6.3 Record in Data Privacy Log (Annexure-5).

7. Re-Consent
7.1 Conduct electronic re-consent when protocol amendments require it.
7.2 Document in Re-Consent Log (Annexure-6).

8. Inspection Readiness
8.1 Maintain inspection-ready logs for regulators.
8.2 Document inspection simulations in Inspection Readiness Log (Annexure-7).

Abbreviations

SOP: Standard Operating Procedure
CRO: Contract Research Organization
QA: Quality Assurance
EC/IRB: Ethics Committee/Institutional Review Board
GDPR: General Data Protection Regulation
HIPAA: Health Insurance Portability and Accountability Act
TMF: Trial Master File
ISF: Investigator Site File
FDA: Food and Drug Administration
EMA: European Medicines Agency

Documents

eConsent System Validation Log (Annexure-1)
EC/IRB Approval Log (Annexure-2)
Identity Verification Log (Annexure-3)
eConsent Completion Log (Annexure-4)
Data Privacy Log (Annexure-5)
Re-Consent Log (Annexure-6)
Inspection Readiness Log (Annexure-7)

References

Version: 1.0

Approval Section

Prepared By	Ravi Kumar, Regulatory Compliance Specialist
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Head Clinical Operations

Annexures

Annexure-1: eConsent System Validation Log

Date	System Name	Validation Status	Performed By	Comments
01/09/2025	eConsentApp v3.2	Validated	IT QA	Part 11 Compliant

Annexure-2: EC/IRB Approval Log

Date	Protocol ID	Approval By	Status	Comments
02/09/2025	EC-TRIAL-01	IRB-01	Approved	eConsent Approved

Annexure-3: Identity Verification Log

Date	Subject ID	Verification Method	Verified By	Status
03/09/2025	S101	ID Upload + OTP	Site Staff	Completed

Annexure-4: eConsent Completion Log

Date	Subject ID	Form Version	Consent Given	Investigator
03/09/2025	S101	v1.0	Yes	Investigator

Annexure-5: Data Privacy Log

Date	System	Privacy Measure	Reviewed By	Status
04/09/2025	eConsentApp v3.2	Encryption Enabled	QA Officer	Compliant

Annexure-6: Re-Consent Log

Date	Subject ID	Amendment	Re-Consent Obtained	By Whom
06/09/2025	S101	Protocol Amendment v2.0	Yes	Investigator

Annexure-7: Inspection Readiness Log

Date	Regulatory Body	Inspection Simulation	Performed By	Status
08/09/2025	FDA	Mock Inspection	QA Team	Completed

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head Clinical Operations

For more SOPs visit: Pharma SOP